RESUMO
L-Selectin is a calcium-dependent mammalian lectin that mediates lymphocyte trafficking by recognizing sialylated ligands on high endothelial venules in lymph nodes. Although L-selectin probably mediates neutrophil extravasation into nonlymphoid tissues, no corresponding ligand has been characterized. Staining of cultured endothelial cells with an L-selectin chimera (LS-Rg) showed an internal pool of ligands. Metabolic labeling with sulfur-35-labeled sulfate revealed heparin lyase-sensitive ligands that bound LS-Rg in a calcium-dependent, sialic acid-independent manner. A fraction of commercial heparin bound to LS-Rg and LS-Rg bound to heparin-agarose, both in a calcium-dependent manner. Thus, L-selectin recognizes endothelial heparin-like chains, which could be physiological ligands mediating leucocyte trafficking.
Assuntos
Cálcio/fisiologia , Moléculas de Adesão Celular/metabolismo , Endotélio Vascular/metabolismo , Glicosaminoglicanos/metabolismo , Animais , Antitrombina III/metabolismo , Bovinos , Linhagem Celular , Eletroforese em Gel de Poliacrilamida , Endotélio Linfático/metabolismo , Heparina/metabolismo , Humanos , Selectina L , Ligantes , Ligação Proteica , Ensaio Radioligante , Proteínas Recombinantes de Fusão/metabolismoRESUMO
Essentials Plg-RKT-/- female mice give birth, but no offspring of Plg-RKT-/- female mice survive to weaning. Causal mechanisms of potential lactational failure in Plg-RKT-/- mice are unknown. Plg-RKT regulates extracellular matrix remodeling, cell proliferation, apoptosis, fibrin surveillance. Plg-RKT is essential for lactogenesis and mammary lobuloalveolar development. SUMMARY: Background Lactational competence requires plasminogen, the zymogen of the serine protease, plasmin. Plg-RKT is a unique transmembrane plasminogen receptor that promotes plasminogen activation to plasmin on cell surfaces. Plg-RKT-/- mice are viable, but no offspring of Plg-RKT-/- female mice survive to weaning. Objectives We investigated potential lactational failure in Plg-RKT-/- mice and addressed causal mechanisms. Methods Fibrin accumulation, macrophage infiltration, processing of extracellular matrix components, effects of genetic deletion of fibrinogen, expression of fibrosis genes, and proliferation and apoptosis of epithelial cells were examined in lactating mammary glands of Plg-RKT-/- and Plg-RKT+/+ mice. Results Milk was not present in the stomachs of offspring of Plg-RKT-/- female mice and the pups were rescued by foster mothers. Although the mammary ductal tree developed normally in Plg-RKT-/- glands, lobuloalveolar development was blocked by a hypertrophic fibrotic stroma and infiltrating macrophages were present. A massive accumulation of fibrin was also present in Plg-RKT-/- alveoli and ducts. Although this accumulation was decreased when Plg-RKT-/- mice were made genetically heterozygous for fibrinogen, defects in lobuloalveolar development were not rescued by fibrinogen heterozygosity. Transcriptional profiling revealed that EGF was downregulated 12-fold in Plg-RKT-/- glands. Furthermore, proliferation of epithelial cells was not detectable. In addition, the pro-survival protein, Mcl-1, was markedly downregulated and apoptosis was observed in Plg-RKT-/- but not Plg-RKT+/+ glands. Conclusions Plg-RKT is essential for lactogenesis and functions to maintain the appropriate stromal extracellular matrix environment, regulate epithelial cell proliferation and apoptosis, and, by regulating fibrinolysis, preserve alveolar and ductal patency.
Assuntos
Fibrina/metabolismo , Lactação , Glândulas Mamárias Animais/metabolismo , Morfogênese , Receptores de Superfície Celular/deficiência , Animais , Apoptose , Proliferação de Células , Matriz Extracelular/metabolismo , Matriz Extracelular/patologia , Feminino , Fibrinogênio/genética , Fibrinogênio/metabolismo , Fibrose , Genótipo , Macrófagos/metabolismo , Macrófagos/patologia , Glândulas Mamárias Animais/crescimento & desenvolvimento , Glândulas Mamárias Animais/patologia , Camundongos da Linhagem 129 , Camundongos Endogâmicos C57BL , Camundongos Knockout , Fenótipo , Receptores de Superfície Celular/genética , Receptores de Superfície Celular/metabolismoRESUMO
Essentials Plg-RKT is a novel integral membrane plasminogen receptor. The functions of Plg-RKT in vivo are not known. Plg-RKT is a key player in macrophage recruitment in the inflammatory response in vivo. Plg-RKT deficiency is not compatible with survival of the species. SUMMARY: Background Plg-RKT is a novel integral membrane plasminogen receptor that binds plasminogen via a C-terminal lysine exposed on the cell surface and promotes plasminogen activation on the cell surface by both tissue plasminogen activator and urokinase plasminogen activator. Objectives To evaluate the role of Plg-RKT in vivo we generated Plg-RKT-/- mice using a homologous recombination technique. Methods We characterized the effect of Plg-RKT deletion on reproduction, viability, health and spontaneous thrombosis and inflammation. Results Plg-RKT-/- mice were viable and fertile. Survival of Plg-RKT-/- mice and Plg-RKT+/+ littermates was not significantly different. However, quite strikingly, all pups of Plg-RKT-/- females died within 2 days of birth, consistent with a lactation defect in Plg-RKT-/- mothers. Additionally, there was a significant effect of Plg-RKT deficiency on the growth rates of female, but not male, mice. In experimental peritonitis studies, Plg-RKT-/- mice exhibited a marked defect in macrophage recruitment. As a contributing mechanism, the capacity of Plg-RKT-/- macrophages for plasminogen binding was markedly decreased. Conclusions These studies demonstrate that Plg-RKT is required for plasminogen binding and macrophage migration in vivo. In addition, Plg-RKT deficiency is not compatible with survival of the species, due to the death of all offspring of Plg-RKT-/- females. This new mouse model will be important for future studies aimed at delineating the role of cell surface plasminogen activation in challenge and disease models in vivo.
Assuntos
Macrófagos/citologia , Plasminogênio/química , Receptores de Superfície Celular/química , Animais , Contagem de Células Sanguíneas , Membrana Celular/metabolismo , Feminino , Fibrinolisina/química , Homeostase , Humanos , Inflamação , Masculino , Camundongos , Camundongos Transgênicos , Ligação Proteica , Domínios Proteicos , Terapia TrombolíticaRESUMO
BACKGROUND: Advanced (stage 4) cases of neuroblastoma, a childhood cancer of the nervous system, are associated with high relapse rates, even after intensive chemotherapy, radiotherapy, and autologous bone marrow transplantation. Therefore, the use of monoclonal antibodies directed against the neuroblastoma tumor marker disialoganglioside GD2 (GD2), in combination with recombinant human interleukin 2 (rhIL-2), is under clinical investigation. We hypothesize that targeted cytokine immunotherapy with a recombinant anti-GD2 antibody-interleukin 2 fusion protein (ch14.18-IL-2) is superior to a combination of ch14.18 and rhIL-2. Our purpose was as follows: 1) to develop a syngeneic model for murine neuroblastoma that expresses GD2 and features both experimental and spontaneous metastases to bone marrow and liver, and 2) to assess anti-GD2-targeted IL-2 therapy in this mode. METHODS: A hybrid neuroblastoma cell line was used to generate the GD2-positive NXS2 cell line. Bone marrow and liver metastases were quantified by reverse transcription-polymerase chain reaction for tyrosine hydroxylase and by organ weight or counts of macroscopic tumor foci, respectively. All P values reported are two-sided. RESULTS: Injection of NXS2 cells resulted in disseminated bone marrow and liver metastases exhibiting stable, but heterogeneous expression of GD2. Treatment with fusion protein (10 microg/day for 6 days) effectively suppressed growth of both experimental and spontaneous metastases to bone marrow and liver (P<.001). In contrast, a mixture of rhIL-2 and ch14.18 at equivalent dose levels was inefficient. Only mice treated with ch14.18-IL-2 showed a twofold prolongation in life span (P<.001). CONCLUSION: Targeted IL-2 therapy with a ch14.18-IL-2 fusion protein elicits an effective antitumor response. Our data suggest that a study of ch14.18-IL-2 as an adjuvant treatment in patients with minimal residual disease may be of value.
Assuntos
Antineoplásicos/uso terapêutico , Neoplasias da Medula Óssea/terapia , Interleucina-2/uso terapêutico , Neuroblastoma/terapia , Animais , Anticorpos Monoclonais/uso terapêutico , Biomarcadores Tumorais/imunologia , Neoplasias da Medula Óssea/imunologia , Neoplasias da Medula Óssea/secundário , Feminino , Gangliosídeos/imunologia , Incidência , Neoplasias Hepáticas/secundário , Neoplasias Hepáticas/terapia , Camundongos , Metástase Neoplásica , Neuroblastoma/imunologia , Neuroblastoma/secundário , Reação em Cadeia da Polimerase/métodos , Transcrição Gênica , Células Tumorais CultivadasRESUMO
Monoclonal antibodies KS1/4, KS1/9, and KS1/17 were developed in this laboratory from a fusion of the murine myeloma cell line P3X63Ag8 with spleens of BALB/c mice previously primed with UCLA P3 cells derived from a human adenocarcinoma of the lung. Monoclonal antibodies KS1/4 and KS1/17 seemed to recognize similar glycoprotein antigens on the lung carcinoma cells by indirect immunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis. However, mapping of [3H]lysine- and [3H]arginine-labeled tryptic peptides of antigens in specific immunoprecipitates of lung carcinoma cells by high-pressure liquid chromatography revealed a one peptide difference. Antibody KS1/9 did not immunoprecipitate any identifiable protein from detergent extracts of the immunizing cell line by routine methods and appears to detect a glycolipid antigen. Immunocytochemical analysis of tissue sections showed this monoclonal antibody to be reactive with adenocarcinomas of the lung and not with the other histological types of lung carcinoma or normal tissue. Monoclonal antibodies KS1/4 and KS1/17, however, reacted with 3 major histological types of lung cancer and minimally with the proximal tubules of normal kidney and the epithelium of bronchioles.
Assuntos
Adenocarcinoma/imunologia , Anticorpos Monoclonais/imunologia , Antígenos de Neoplasias/análise , Neoplasias Pulmonares/imunologia , Animais , Cromatografia Líquida de Alta Pressão , Reações Cruzadas , Ensaio de Imunoadsorção Enzimática , Humanos , Técnicas Imunoenzimáticas , Camundongos , Camundongos Endogâmicos BALB C/imunologiaRESUMO
Antibody-cytokine fusion proteins can target biologically active cytokines to various tumor sites, achieving local concentrations sufficient to induce host immune responses leading to tumor elimination. Here, we demonstrate the therapeutic efficacy of a tumor-specific antibody-lymphotoxin fusion protein (ch225-LT) on xenografted pulmonary metastases of human melanoma. In vitro studies indicated a direct cytotoxic effect of such construacts on melanoma cells via the induction of apoptosis, as demonstrated by cell cycle analysis and DNA fragmentation. However, ch225-LT lacked any therapeutic effect in immune deficient C.B17 scid/beige and scid/scid mice, indicating the insufficiency of this direct mechanism in vivo. In contrast, in athymic nu/nu mice, ch225-LT completely inhibited outgrowth of the xenografted tumor. This therapeutic effect was accompanied by infiltrations of CD45+, Mac-1+, and asialo-GM1+ cells into the tumor; B220+ cells were present in the surrounding tissue and the periphery of the tumor. The functional role of asialo-GM2+ cells was confirmed by in vivo depletion studies. Our data indicate that an antibody-lymphotoxin fusion protein effectively inhibits the growth of disseminated melanoma metastases by mechanisms that function in the absence of mature T cells, but require B, NK, and other asialo-GM1+ cells.
Assuntos
Linfócitos B/imunologia , Imunotoxinas/uso terapêutico , Neoplasias Pulmonares/secundário , Neoplasias Pulmonares/terapia , Linfotoxina-alfa/uso terapêutico , Melanoma/secundário , Melanoma/terapia , Animais , Anticorpos Monoclonais/uso terapêutico , Apoptose , Ciclo Celular , Morte Celular , Divisão Celular/efeitos dos fármacos , Dano ao DNA , Humanos , Imuno-Histoquímica , Inflamação , Neoplasias Pulmonares/imunologia , Neoplasias Pulmonares/patologia , Depleção Linfocítica , Melanoma/imunologia , Melanoma/patologia , Camundongos , Camundongos Nus , Camundongos SCID , Proteínas Recombinantes de Fusão/uso terapêutico , Especificidade da Espécie , Transplante HeterólogoRESUMO
A murine monoclonal antibody (monoclonal antibody 126) produced against cultured human neuroblastoma cells (LAN-1) was found to be specifically directed to a disialoganglioside (GD2) antigen preferentially expressed on both cell lines and tissues derived from melanoma and neuroblastoma. In enzyme-linked immunosorbent assays, monoclonal antibody 126 failed to react with leukemic and lymphoblastoid cells as well as with a variety of carcinoma and sarcoma cell lines. Immunohistological analysis by the immunoperoxidase technique revealed strong reactivity of monoclonal antibody 126 with frozen and formaldehyde-fixed neuroblastoma and melanoma tissues. Tissues from patients with glioma or with small cell cancer of the lung showed faint staining, whereas those from individuals with sarcoma, lymphoma, and a variety of other neoplasms proved to be negative. Sera of neuroblastoma patients showed significantly elevated GD2 levels compared to normal children (p less than 0.001) and children with other tumors (p less than 0.001) as determined by a quantitative competitive enzyme-linked immunosorbent assay. Furthermore, the GD2 serum level of one neuroblastoma patient, when followed serially, was found to correlate with progression of disease, suggesting the potential usefulness of this assay for the diagnosis and monitoring of neuroblastoma.
Assuntos
Gangliosídeos/análise , Neuroblastoma/análise , Anticorpos Monoclonais , Linhagem Celular , Ensaio de Imunoadsorção Enzimática , Gangliosídeos/sangue , Humanos , Neoplasias/análise , Neuroblastoma/sangue , Neuroblastoma/patologiaRESUMO
The disialoganglioside GD3 is a major antigen in human melanomas that can undergo 9-O-acetylation of the outer sialic acid (giving 9-OAc-GD3). Monoclonal antibody SGR37 detects a different modification of the GD3, de-N-acetylation of the 5-N-acetyl group (giving de-N-Ac-GD3). We found that conventional immunohistochemistry of the SGR37 antigen is limited by a reduction in reactivity upon fixation with aldehydes (which presumably react with the free amino group) or with organic reagents (which can extract glycolipids). We optimized conditions for detection of this antigen in unfixed frozen tissue sections and studied its distribution in human tissues and tumors. It is expressed at low levels in a few blood vessels, infiltrating mononuclear cells in the skin and colon, and at moderate levels in skin melanocytes. In contrast, the antigen accumulates at high levels in many melanomas and in some lymphomas but not in carcinomas. In positive melanomas, expression is sometimes more intense and widespread than that of GD3. Both 9-O-acetylation and de-N-acetylation of GD3 seem to occur after its initial biosynthesis. Isotype-matched antibodies against GD3, 9-O-acetyl-GD3 and de-N-acetyl-GD3 were used to compare their subcellular localization and trafficking. 9-O-acetyl-GD3 colocalizes with GD3 predominantly on the cell surface and partly in lysosomal compartments. In contrast, de-N-acetyl-GD3 has a diffuse intracellular location. Adsorptive endocytosis of antibodies indicates that whereas GD3 remains predominantly on the cell surface, de-N-acetyl-GD3 is efficiently internalized into a compartment that is distinct from lysosomes. Rounding up of melanoma cells occurring during growth in culture is associated with relocation of the internal pool of de-N-acetyl-GD3 to the cell surface. Thus, a minor modification of the polar head group of a tumor-associated glycosphingolipid can markedly affect the subcellular localization and trafficking of the whole molecule. The high levels of the SGR37 antigen in melanomas and lymphomas, its selective endocytosis from the cell surface, and its relocation to the cell surface of rounded up cells suggest potential uses in diagnostic or therapeutic approaches to these diseases.
Assuntos
Antígenos de Neoplasias/metabolismo , Gangliosídeos/metabolismo , Neoplasias/metabolismo , Antígenos de Superfície/metabolismo , Carcinoma/metabolismo , Carcinoma/patologia , Ciclo Celular/fisiologia , Membrana Celular/metabolismo , Humanos , Linfoma/metabolismo , Linfoma/patologia , Lisossomos/metabolismo , Melanoma/metabolismo , Melanoma/patologia , Neoplasias/patologia , Frações Subcelulares/metabolismo , Distribuição TecidualRESUMO
A recombinant humanized antibody-interleukin 2 fusion protein (huKS1/4-IL-2) was used to direct IL-2 to the tumor microenvironment and elicit a T cell-mediated eradication of established pulmonary and hepatic CT26-KSA colon carcinoma metastases in syngeneic BALB/c mice. This antitumor effect was specific because a fusion protein, which was nonreactive with these tumor cells, failed to exert any such effect. The efficacy of the huKS1/4-IL-2 fusion protein in eliminating metastases was documented because mixtures of monoclonal antibody huKS1/4 with recombinant human IL-2 were ineffective and, at best, only partially reduced tumor load. Two lines of evidence indicated the eradication of metastases and the absence of minimal residual disease in animals treated with the fusion protein: first, the lack of detection of CT26-KSA cells by reverse transcription-PCR, which can detect one tumor cell in 10(6) liver cells; and second, the tripling of life span. The effector mechanism involved in this tumor eradication is dependent on T cells because the IL-2-directed therapy is ineffective in T cell-deficient SCID mice. The essential effector cells were further characterized as CD8+ T cells by in vivo depletion studies. Such T cells, isolated from tumor-bearing mice after fusion protein therapy, elicited MHC class I-restricted cytotoxicity in vitro against colon carcinoma target cells. Taken together, these data indicate that fusion protein-directed IL-2 therapy induces a T cell-dependent host immune response capable of eradicating established colon cancer metastases in an animal tumor model.
Assuntos
Moléculas de Adesão Celular , Neoplasias do Colo/patologia , Imunotoxinas/uso terapêutico , Interleucina-2/uso terapêutico , Neoplasias Hepáticas/secundário , Neoplasias Hepáticas/terapia , Neoplasias Pulmonares/secundário , Neoplasias Pulmonares/terapia , Proteínas Recombinantes de Fusão/uso terapêutico , Animais , Anticorpos/uso terapêutico , Antígenos de Neoplasias/análise , Neoplasias do Colo/imunologia , Neoplasias do Colo/metabolismo , Molécula de Adesão da Célula Epitelial , Feminino , Humanos , Imunidade Celular , Imunotoxinas/farmacocinética , Interleucina-2/farmacocinética , Células Matadoras Naturais/imunologia , Neoplasias Hepáticas/imunologia , Neoplasias Hepáticas/metabolismo , Neoplasias Pulmonares/imunologia , Neoplasias Pulmonares/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Camundongos SCID , Proteínas Recombinantes de Fusão/farmacocinética , Subpopulações de Linfócitos T/imunologia , Células Tumorais CultivadasRESUMO
Preclinical studies have demonstrated a relationship between DNA mismatch repair (MMR) status and sensitivity to cisplatin and carboplatin. MMR-deficient cells are resistant to both drugs, and selection for cisplatin resistance in vitro is sometimes accompanied by loss of MMR protein expression. We used immunohistochemical staining techniques to investigate hMLH1 and hMSH2 expression in paired ovarian tumor sections from 54 ovarian cancer patients before and after platinum-based therapy. We sought associations between hMLH1 and hMSH2 protein expression and clinical parameters known to be of prognostic significance as well as response to treatment and overall survival. hMLH1 and hMSH2 staining decreased significantly after platinum-based therapy. The percent of malignant cells that stained positive correlated with the intensity of nuclear staining for both proteins; staining for hMLH1 correlated well with staining for hMSH2. Unexpectedly, expression of nuclear hMLH1 correlated negatively with response to treatment. Expression of nuclear hMLH1 and hMSH2 was positively correlated with pretreatment CA125 level, and expression of nuclear hMSH2 was positively correlated with change in CA125 level after treatment. Tumor stage was associated with expression of nuclear hMSH2, and tumor histological subtype was associated with both hMLH1 and hMSH2 staining. No association was found between expression of either protein and overall survival. These results indicate that the tumor is biologically altered after chemotherapy consistent with treatment-induced selection for cells expressing lower hMLH1 and hMSH2 levels. However, immunohistochemical staining for either hMLH1 or hMSH2 was not highly predictive of drug sensitivity as measured by response or survival.
Assuntos
Antineoplásicos/uso terapêutico , Carboplatina/uso terapêutico , Cisplatino/uso terapêutico , Proteínas de Ligação a DNA , Proteínas de Neoplasias/biossíntese , Neoplasias Ovarianas/metabolismo , Proteínas Proto-Oncogênicas/biossíntese , Proteínas Adaptadoras de Transdução de Sinal , Antígeno Ca-125/análise , Proteínas de Transporte , Interpretação Estatística de Dados , Feminino , Humanos , Imuno-Histoquímica , Proteína 1 Homóloga a MutL , Proteína 2 Homóloga a MutS , Proteínas de Neoplasias/análise , Proteínas Nucleares , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/patologia , Proteínas Proto-Oncogênicas/análiseRESUMO
Effective therapy is needed to improve the survival of patients with advanced lung cancers. We studied the effects of a selective metalloprotease inhibitor, AG3340, on chemoresistant human non-small cell lung cancer tumors (line MV522) in vivo. Mice bearing s.c. tumors were given twice-daily oral doses of AG3340. As a single agent, AG3340 inhibited angiogenesis (up to 77%) and tumor growth (up to 65%) in a dose-dependent manner at well-tolerated daily doses up to 400 mg/kg/day and induced significant tumor necrosis. In contrast, tumors were relatively insensitive to carboplatin with approximately 25% growth inhibition observed at a maximum tolerated dose of approximately 30 mg/kg/week (given i.p., twice weekly). Carboplatin inhibited tumor growth markedly only at toxic doses, demonstrating a superior therapeutic index of AG3340 to carboplatin in this tumor model. A suboptimal dose of AG3340, when used in combination with an ineffective maximum tolerated dose of carboplatin, resulted in greater tumor growth inhibitions than those produced by either agent alone. Similarly, growth inhibition was enhanced when AG3340 was used in combination with paclitaxel. Cotreatment with carboplatin did not alter AG3340 plasma concentrations achieved acutely after oral dosing. These data demonstrate an antiangiogenic and antitumor effect of AG3340 when used as a single agent and enhanced growth inhibitions when AG3340 is used in combination with cytotoxic agents. These data suggest that treatment with this novel matrix metalloprotease inhibitor may be beneficial in advanced lung cancers and other chemoresistant malignancies.
Assuntos
Antineoplásicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Compostos Orgânicos , Animais , Antineoplásicos/sangue , Antineoplásicos/toxicidade , Antineoplásicos Fitogênicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/toxicidade , Carboplatina/administração & dosagem , Carboplatina/toxicidade , Carcinoma Pulmonar de Células não Pequenas/patologia , Modelos Animais de Doenças , Interações Medicamentosas , Resistencia a Medicamentos Antineoplásicos , Quimioterapia Combinada , Feminino , Humanos , Neoplasias Pulmonares/patologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Transplante de Neoplasias , Neovascularização Patológica , Paclitaxel/administração & dosagem , Transplante Heterólogo , Resultado do Tratamento , Células Tumorais CultivadasRESUMO
We describe a human integral cell surface glycoprotein (Mr 142 kD), recognized by monoclonal antibody M2B3. This glycoprotein is absent from resting peripheral blood lymphocytes, but becomes expressed in significant levels with mitogen activation. The M2B3 glycoprotein is present on epithelial cells in the basal layer of epidermal and esophageal tissue as well as in several fresh tumors examined. In addition, it is present on smooth muscle tissue throughout the gastrointestinal tract, but is absent from smooth muscle from several other tissue sources, skeletal muscle and cardiac muscle. The M2B3 glycoprotein is similar, but not identical, in apparent Mr to a transformation-associated glycoprotein, Q14. Further, the M2B3 and Q14 species are related antigenically. Nonetheless, M2B3 and Q14 are distinct glycoproteins based on clear differences in cell distribution and in partial peptide mapping. The M2B3 antigen described herein is sulfated on tyrosine, and represents one of the few cell surface proteins described to date that is sulfated on tyrosine residues. Our studies suggest the function of the M2B3 glycoprotein is likely to be associated with cell proliferation of cell adhesion.
Assuntos
Glicoproteínas de Membrana/metabolismo , Tirosina/análogos & derivados , Anticorpos Monoclonais , Linhagem Celular , Citometria de Fluxo , Humanos , Imuno-Histoquímica , Ativação Linfocitária , Glicoproteínas de Membrana/química , Glicoproteínas de Membrana/imunologia , Peso Molecular , Mapeamento de Peptídeos , Sulfatos , Distribuição Tecidual , Tirosina/metabolismoRESUMO
The process of adhesion to endothelial cells is an important step in the progression to metastatic disease. The use of human neoplastic cell lines (now increasingly used in the study of the mechanisms of metastasis) in studying interactions with normal endothelial cells is therefore pertinent. In this report, the enhanced ability of a metastatic variant, MV522, of a human lung carcinoma cell line to adhere to endothelial cell monolayers is demonstrated. The ability to spontaneously metastasize from subcutaneous sites in athymic mice, of in vitro selected endothelial adhesive subpopulations of MV522 is also shown.
Assuntos
Adesão Celular , Endotélio Vascular/citologia , Neoplasias Pulmonares/patologia , Metástase Neoplásica/patologia , Animais , Contagem de Células , Divisão Celular , Linhagem Celular , Feminino , Humanos , Neoplasias Pulmonares/secundário , Camundongos , Camundongos Nus , Transplante de NeoplasiasRESUMO
We studied AG3340, a potent metalloproteinase (MMP) inhibitor with pM affinities for inhibiting gelatinases (MMP-2 and -9), MT-MMP-1 (MMP-14), and collagenase-3 (MMP-13) in many tumor models. AG3340 produced dose-dependent pharmacokinetics and was well tolerated after intraperitoneal (i.p.) and oral dosing in mice. Across human tumor models, AG3340 produced profound tumor growth delays when dosing began early or late after tumor implantation, although all established tumor types did not respond to AG3340. A dose-response relationship was explored in three models: COLO-320DM colon, MV522 lung, and MDA-MB-435 breast. Dose-dependent inhibitions of tumor growth (over 12.5-200 mg/kg given twice daily, b.i.d.) were observed in the colon and lung models; and in a third (breast), maximal inhibitions were produced by the lowest dose of AG3340 (50 mg/kg, b.i.d.) that was tested. In another model, AG3340 (100 mg/kg, once daily, i.p.) markedly inhibited U87 glioma growth and increased animal survival. AG3340 also inhibited tumor growth and increased the survival of nude mice bearing androgen-independent PC-3 prostatic tumors. In a sixth model, KKLS gastric, AG3340 did not inhibit tumor growth but potentiated the efficacy of Taxol. Importantly, AG3340 markedly decreased tumor angiogenesis (as assessed by CD-31 staining) and cell proliferation (as assessed by bromodeoxyuridine incorporation), and increased tumor necrosis and apoptosis (as assessed by hematoxylin and eosin and TUNEL staining). These effects were model dependent, but angiogenesis was commonly inhibited. AG3340 had a superior therapeutic index to the cytotoxic agents, carboplatin and Taxol, in the MV522 lung cancer model. In combination, AG3340 enhanced the efficacy of these cytotoxic agents without altering drug tolerance. Additionally, AG3340 decreased the number of murine melanoma (B16-F10) lesions arising in the lung in an intravenous metastasis model when given in combination with carboplatin or Taxol. These studies directly support the use of AG3340 in front-line combination chemotherapy in ongoing clinical trials in patients with advanced malignancies of the lung and prostate.
Assuntos
Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias do Colo/tratamento farmacológico , Glioma/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Metaloendopeptidases/antagonistas & inibidores , Neovascularização Patológica/prevenção & controle , Compostos Orgânicos , Animais , Apoptose/efeitos dos fármacos , Neoplasias da Mama/irrigação sanguínea , Neoplasias da Mama/patologia , Divisão Celular/efeitos dos fármacos , Linhagem Celular , Neoplasias do Colo/irrigação sanguínea , Neoplasias do Colo/patologia , Feminino , Glioma/patologia , Humanos , Cinética , Neoplasias Pulmonares/irrigação sanguínea , Neoplasias Pulmonares/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Nus , Camundongos SCID , Inibidores de Proteases/uso terapêutico , Transplante HeterólogoRESUMO
An 87-year-old woman with follicular carcinoma of the thyroid gland is described, who developed ventricular tachycardia (VT) with loss of consciousness. The patient had developed widespread metastatic follicular carcinoma and succumbed to her disease. At autopsy, intracardiac metastases were found and were documented to be of thyroidal origin by the presence of thyroglobulin, using immunohistological staining techniques, using a specific antithyroglobulin antibody.
Assuntos
Adenocarcinoma/secundário , Neoplasias Cardíacas/secundário , Neoplasias da Glândula Tireoide/patologia , Adenocarcinoma/patologia , Idoso , Idoso de 80 Anos ou mais , Endocárdio , Humanos , MasculinoRESUMO
Clonal subpopulations of neoplastic cells were derived, in soft agar, from the spontaneously metastazing variant (MV522) of a human lung carcinoma cell line. The ability of these clones to spontaneously metastasize from subcutaneous sites in athymic mice was then tested. A variation in metastatic ability was expected with the derivation of some low metastatic clones and some high metastatic ones. However, all of the derived clones, although equally tumorigenic, were less metastatic than the parental variant. These clonal cell lines can now be used in a systematic analysis of events associated with the reversion to a less malignant state.
Assuntos
Variação Genética , Neoplasias Pulmonares/patologia , Metástase Neoplásica , Animais , Divisão Celular , Linhagem Celular , Células Clonais , Feminino , Humanos , Isoenzimas/análise , Cariotipagem , Neoplasias Pulmonares/genética , Camundongos , Camundongos Nus , Transplante de Neoplasias , Transplante Heterólogo , Células Tumorais Cultivadas/citologiaRESUMO
OBJECTIVES: We tested the in vitro and in vivo growth effects of estradiol and tamoxifen citrate to determine whether patients with laryngeal carcinoma could benefit from antiestrogen therapy as demonstrated for cancers of other estrogen-responsive organs. DESIGN: A comparison of growth effects of the hormones relative to controls by using a tetrazolium dye reduction assay and nude mice. MATERIALS: Two estrogen-positive laryngeal carcinoma cell lines (UMSCC5 and UMSCC11B) and athymic mice were used. RESULTS: There were marked growth inhibitory effects of tamoxifen alone in concentrations of 3 to 8 mumol/L on both cell lines. There were no in vitro growth effects of estradiol-17 beta alone in concentrations of 0.1 to 9.6 mumol/L, but there was antagonism of the estradiol to the growth inhibitory effects of tamoxifen. In athymic mice, estradiol markedly stimulated the growth of UMSCC5, whereas tamoxifen inhibited growth. CONCLUSIONS: These results support the concept of chemotherapeutic growth inhibition of estrogen receptor-positive laryngeal cancer with antiestrogens.
Assuntos
Carcinoma/tratamento farmacológico , Estradiol/farmacologia , Neoplasias Laríngeas/tratamento farmacológico , Tamoxifeno/farmacologia , Animais , Carcinoma/metabolismo , Estradiol/uso terapêutico , Feminino , Humanos , Neoplasias Laríngeas/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Receptores de Estrogênio/efeitos dos fármacos , Tamoxifeno/uso terapêutico , Células Tumorais CultivadasRESUMO
We describe a chemosensitivity testing of head and neck tumors, in which a native-state histoculture, ie, a three-dimensional culture system that maintains important in vivo properties, including tissue architecture, was used. Fifteen specimens of head and neck tumors were evaluated for sensitivity to the following drugs: cisplatin (DDP) at concentrations of 1.5, 15, and 37.5 micrograms/mL; fluorouracil at concentrations of 4.0, 40, and 100 micrograms/mL; and combinations of cisplatin and fluorouracil in corresponding doses. Growth and measurement of drug responses were successfully completed in 10 specimens (five others were contaminated, four of them prior to instituting rigorous antibiotic washes). The results indicated cisplatin sensitivity in five of 10 patients; fluorouracil sensitivity in four of 10 patients; and fluorouracil-cisplatin sensitivity in seven of eight patients. Our preliminary results indicate that the native-state histoculture technique is feasible to test chemosensitivity of head and neck tumors.
Assuntos
Carcinoma/tratamento farmacológico , Cisplatino/uso terapêutico , Fluoruracila/uso terapêutico , Neoplasias de Cabeça e Pescoço/tratamento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma/patologia , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/patologia , Divisão Celular , Sobrevivência Celular/efeitos dos fármacos , Cisplatino/administração & dosagem , Ensaios de Seleção de Medicamentos Antitumorais , Fluoruracila/administração & dosagem , Neoplasias de Cabeça e Pescoço/patologia , Técnicas Histológicas , Humanos , Estadiamento de Neoplasias , Células Tumorais CultivadasRESUMO
Adenoviruses can produce severe disease, especially in patients who are immunosuppressed. We present a unique case in which adenovirus type 5 was demonstrated retrospectively, by using immunohistochemical methods, in the appendix of a liver transplant donor. The donor had intussusception, which has been associated with adenovirus infection. Both the initial and a second liver transplant in the recipient were severely damaged by adenovirus type 5. These findings were demonstrated immunohistochemically, as well as on electron microscopy. The recipient died due to the infection and ensuing complications.
Assuntos
Infecções por Adenoviridae/patologia , Hepatite Viral Humana/patologia , Transplante de Fígado/patologia , Infecções por Adenoviridae/diagnóstico , Hepatite Viral Humana/diagnóstico , Humanos , Imuno-Histoquímica , Lactente , Fígado/ultraestrutura , Masculino , Microscopia EletrônicaRESUMO
In this article, we describe a case of a cellular neurilemmoma with focal granular cell elements. The Schwann cells showed S100 and Leu-7 immunoreactivity. The granular cells were periodic acid-Schiff-positive, diastase resistant with strong S100 immunoreactivity. Electron microscopy showed electron dense, heterogeneous granules in the granular cells and interdigitating processes and elongated nuclei of the Schwann cells. Although many granular cell tumors are believed to be derived from Schwann cells, neoplasms with both elements are rarely presented.